Christiane B. Knobbe-Thomsen

TL;DR: It is demonstrated that synthesis of the antioxidant glutathione (GSH), driven by GCLM, is required for cancer initiation and combined inhibition of GSH and thioredoxin antioxidant pathways leads to a synergistic cancer cell death in vitro and vivo, demonstrating the importance of these two antioxidants to tumor progression and as potential targets for therapeutic intervention.

TL;DR: It is illustrated how advances in the molecular genetics of gliomas can promote the development and clinical translation of novel pathogenesis-based therapeutic approaches, thereby paving the way towards precision medicine in neuro-oncology.

TL;DR: This work has established CRISPR/Cas9-mediated somatic gene disruption, allowing for in vivo targeting of TSGs and demonstrates the utility of this approach by deleting single (Ptch1) or multiple genes in the mouse brain, resulting in the development of medulloblastoma and glioblastomas.

TL;DR: This work documents coexpression of EGFR and EGFRvIII in primary human glioblastoma that drives transformation and tumorigenesis in a cell-intrinsic manner and demonstrates enhancement of downstream STAT signaling triggered by EGFR-catalyzed phosphorylation of EGfrvIII, implicating EGFR vIII as a substrate for EGFR.

TL;DR: An unexpected role for GSH in restricting serine availability to preserve Treg functionality is revealed, using mice with Treg-specific ablation of the catalytic subunit of glutamate cysteine ligase.